The main goal of the group for the synthesis of new drugs is the design and development of new dosage forms and medicinal products for the treatment of neuropsychiatric and neurodegenerative diseases. To achieve this goal, we combine extensive experimental research and screening with in silico modeling using both traditional and advanced methods of organic synthesis and analytical chemistry. In this process, the most promising lead substances are identified and selected, which are then rigorously tested and validated for further studies in ex vivo and in vivo models with the aim of verifying their potential utility for experimental and preclinical studies and determining their pharmacokinetic profiles and toxicity. Of particular interest is the development of multitargeted ligands that appear to be promising candidates for the treatment of neurodegenerative and psychiatric diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and schizophrenia.